These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 35113275)
41. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Fréling E; Baumann C; Cuny JF; Bigard MA; Schmutz JL; Barbaud A; Peyrin-Biroulet L Am J Gastroenterol; 2015 Aug; 110(8):1186-96. PubMed ID: 26195181 [TBL] [Abstract][Full Text] [Related]
42. Thrombosis in IBD in the Era of JAK Inhibition. Solitano V; Fiorino G; D'Amico F; Peyrin-Biroulet L; Danese S Curr Drug Targets; 2021; 22(1):126-136. PubMed ID: 32881668 [TBL] [Abstract][Full Text] [Related]
43. Impact of thiopurines and tumour necrosis factor antagonists on primary sclerosing cholangitis outcomes in patients with inflammatory bowel disease. Biron A; Beaugerie L; Chazouillères O; Kirchgesner J Aliment Pharmacol Ther; 2022 Sep; 56(5):857-868. PubMed ID: 35789494 [TBL] [Abstract][Full Text] [Related]
44. Lipid Changes After Induction Therapy in Patients with Inflammatory Bowel Disease: Effect of Different Drug Classes and Inflammation. Sleutjes JAM; Roeters van Lennep JE; van der Woude CJ; de Vries AC Inflamm Bowel Dis; 2023 Apr; 29(4):531-538. PubMed ID: 35590447 [TBL] [Abstract][Full Text] [Related]
45. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626 [TBL] [Abstract][Full Text] [Related]
46. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study. Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905 [TBL] [Abstract][Full Text] [Related]
47. Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events. Asscher VER; van der Vliet Q; van der Aalst K; van der Aalst A; Brand EC; van der Meulen-de Jong AE; Oldenburg B; Pierik MJ; van Tuyl B; Mahmmod N; Maljaars PWJ; Fidder HH; Int J Colorectal Dis; 2020 Dec; 35(12):2331-2338. PubMed ID: 32860081 [TBL] [Abstract][Full Text] [Related]
48. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database. Seo GH; Jung SH J Korean Med Sci; 2022 Apr; 37(16):e123. PubMed ID: 35470598 [TBL] [Abstract][Full Text] [Related]
49. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607 [TBL] [Abstract][Full Text] [Related]
50. Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. Kremer JM; Bingham CO; Cappelli LC; Greenberg JD; Madsen AM; Geier J; Rivas JL; Onofrei AM; Barr CJ; Pappas DA; Litman HJ; Dandreo KJ; Shapiro AB; Connell CA; Kavanaugh A ACR Open Rheumatol; 2021 Mar; 3(3):173-184. PubMed ID: 33570260 [TBL] [Abstract][Full Text] [Related]
51. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study. Cottron C; Treton X; Altwegg R; Reenaers C; Amiot A; Fumery M; Vuitton L; Peyrin-Biroulet L; Bouguen G; Dewit O; Nancey S; Caillo L; Roblin X; Beylot-Barry M; Rivière P; Laharie D J Crohns Colitis; 2022 Aug; 16(8):1202-1210. PubMed ID: 35218189 [TBL] [Abstract][Full Text] [Related]
52. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413 [TBL] [Abstract][Full Text] [Related]
53. Risk of Infection and Types of Infection Among Elderly Patients With Inflammatory Bowel Disease: A Retrospective Database Analysis. Khan N; Vallarino C; Lissoos T; Darr U; Luo M Inflamm Bowel Dis; 2020 Feb; 26(3):462-468. PubMed ID: 30980714 [TBL] [Abstract][Full Text] [Related]
54. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599 [TBL] [Abstract][Full Text] [Related]
55. Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. Vedamurthy A; Gangasani N; Ananthakrishnan AN Clin Gastroenterol Hepatol; 2022 Jan; 20(1):88-95. PubMed ID: 33065312 [TBL] [Abstract][Full Text] [Related]
56. Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study. Bernstein CN; Nugent Z; Singh H Am J Gastroenterol; 2021 Jul; 116(7):1476-1484. PubMed ID: 33767104 [TBL] [Abstract][Full Text] [Related]